Ipsen Acquires Epizyme to Expand Oncology Portfolio
August 12, 2022
Ipsen completed its acquisition of Epizyme under a definitive merger agreement, acquiring all outstanding shares for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. The deal expands Ipsen’s oncology portfolio with Epizyme’s lead medicine Tazverik (tazemetostat) and development candidate EZM0414, among other preclinical programs.
- Buyers
- Ipsen
- Targets
- Epizyme, Inc. (Epizyme)
- Sellers
- Royalty Pharma (support agreement; agreed to tender shares)
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.